- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Kankakee Today
By the People, for the People
CSL Invests $1.5B in US Expansion Amid Stock Dip & $750M Buyback
Biotherapeutics leader CSL navigates complex period with major investment and market challenges.
Mar. 14, 2026 at 1:51pm
Got story updates? Submit your updates here. ›
Global biotherapeutics company CSL is investing $1.5 billion to expand its manufacturing facility in Kankakee, Illinois, while also addressing stock performance concerns with a $750 million share buyback program. The expansion aims to boost production of life-sustaining plasma-derived therapies and increase the company's U.S. manufacturing capabilities.
Why it matters
CSL's strategic moves reflect broader trends in the plasma-derived therapies market, including growing global demand and a shift towards regionalizing supply chains. The Kankakee expansion and Horizon 2 technology implementation are key to enhancing the company's manufacturing efficiency and meeting the increasing need for these critical therapies.
The details
The Kankakee expansion, expected to be fully operational by 2031, will create at least 300 new jobs and incorporate CSL's patented Horizon 2 manufacturing process, designed to improve plasma efficiency and immunoglobulin yield. This investment will allow CSL to bring its entire manufacturing process to the U.S., positioning the company to supply 100% of its U.S. demand for immunoglobulin therapies. Meanwhile, CSL has initiated a $750 million share buyback program to address the recent decline in its stock price, which has been impacted by regulatory changes affecting U.S. Medicare payment structures.
- On March 9, 2026, CSL announced the $1.5 billion expansion of its Kankakee, Illinois manufacturing facility.
- The expanded facility is not expected to be fully operational until 2031.
The players
CSL
A global biotherapeutics leader that is investing in the expansion of its manufacturing capabilities and implementing new technologies to enhance production efficiency.
Gordon Naylor
The CEO of CSL, leading the company's strategic balancing act between significant investment and market challenges.
Mary Oates
The Executive Vice President of CSL, who highlighted the potential of the company's Horizon 2 technology to enhance manufacturing efficiency.
JB Pritzker
The Governor of Illinois, emphasizing the importance of CSL's $1.5 billion investment in strengthening the state's biotherapeutics supply chain and creating jobs.
What they’re saying
“Horizon 2 is CSL's patented manufacturing process designed to increase immunoglobulin yield from plasma.”
— Mary Oates, Executive Vice President
What’s next
The expanded Kankakee facility is expected to be fully operational by 2031, which will be a significant milestone for CSL's efforts to increase production of plasma-derived therapies and strengthen its U.S. manufacturing capabilities.
The takeaway
CSL's strategic investments and initiatives, including the Kankakee expansion and the implementation of Horizon 2 technology, demonstrate the company's commitment to meeting the growing global demand for plasma-derived therapies and enhancing its manufacturing efficiency, despite facing short-term market challenges.
